Moderna’s coronavirus vaccine: when will it be available, how much will it cost and how and where to get it?

News for hope in the fight against the pandemic sweeping our planet and affecting the the coronavirus has changed our lives † That is why several pharmaceutical companies are desperately looking for the vaccine that can put an end to this evil.

After Pfizer, who was the first to announce a 90% of effectiveness according to the proven results, now appears Moderna confirms its vaccine against Covid-19 has 94.5% efficacy against the coronavirus.

This was announced by the US company through a press release indicating that a essay for more than 30,000 people, inject half with the vaccine and the other half with a placebo. They emphasize that 7,000 people were over 65 and 5,000 younger, albeit with chronic illnesses linked to a higher risk of being infected by Covid-19, for a total of 42% of the at-risk group.

When is it available, how much does it cost and how and where to get it?

Salvador Illa, Minister of Health, has already set a date for the start of vaccination in Spain. “Vaccination in Spain will begin on December 27 after the day before we have received the first doses of the Pfizer vaccine. Weekly doses will be received that will be distributed equally among the Autonomous Communities and will be administered in accordance with the provisions of the National strategy It is the beginning of the end of the pandemic, but it is not the end. We will have to continue to take measures and to continue to take our responsibility,” assures Illa.

The vaccine comes in two doses 28 days apart and would cost $25, about $21 to exchange, according to the company’s technical director Juan Andrés, in statements to El País.

“We are going to have a vaccine that can stop Covid-19,” said Stephen Hoge, president of the pharmaceutical company.

The forecast is to have 20 million doses ready to be distributed in the United States, a figure that would reach 500 to 1,000 million vaccines worldwide by 2021.

The company, with two supply chains in the United States and Europe, has reported effects such as injection site pain (affecting 2.7% of vaccinees), fatigue (nearly 10%), joint pain (5%) and headache (4.5 %). “These are the symptoms of a moderate flu.”

They estimate that at a temperature of 2 to 8 degrees it can be a stable vaccine and can be stored for 30 days, although at a temperature of -20 degrees it can be stored for six months.

However, it is not the only option, China, Spain, Australia, the United States, Germany (of Dietmar Hopp the hated owner of the Hoffenheim at the head) and England they work at forced marches, the latter of which apparently had the advantage. Members of the Jenner Institute belonging to the Oxford University assured that their hypothetical vaccine (named hAdOx1 nCoV-19) entered a critical phase with Positive results : six healed Rhesu macaque monkeys the animal that is biologically most similar to humans.

Now it’s CureVac, Hopp’s, who reported “positive preclinical results at low doses.” What follows, as announced, are the human trials †

The University of Oxford, in conjunction with the pharmaceutical AstraZeneca, reported that the test was safe in more than 1,000 people and that immunity was developed in late July. The two entities had said the results are promising, although on September 8 they announced the temporary halt of the tests due to “possible side effects” in one of the volunteers who received the dose in the UK. Although the news generated alarm, they clarified from the scientific community that it is a protocol issue common in these types of studies. Although it was initially speculated that the drug was available in September 2020 † we will definitely have to wait a little longer.